ReviewCurrent treatment options in oncology2014
Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients.
Review in Current treatment options in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Quality-adjusted life years in glioma patients: a systematic review on currently available data and the lack of evidence-based utilities.Journal of neuro-oncology · 2019Pooled it
- Factors associated with supportive care needs in glioma patients in the neuro-oncological outpatient setting.Journal of neuro-oncology · 2017Trial
- Prospective inter-individual analysis of quality-adjusted life years (QALYs) in brain tumor patients: A comprehensive assessment of health preferences.International journal of cancer · 2026Article
- The burden of a brain tumor: guiding patient centric care in neuro-oncology.Journal of neuro-oncology · 2022Article
- Article
- Identifying symptom recurrences in primary brain tumor patients using the MDASI-BT and qualitative interviews.Journal of patient-reported outcomes · 2019Article
- Moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma.Patient related outcome measures · 2019Article
- Compliance with patient-reported outcome assessment in glioma patients: predictors for drop out.Neuro-oncology practice · 2018Article
- The Effect of Pet Therapy and Artist Interactions on Quality of Life in Brain Tumor Patients: A Cross-Section of Art and Medicine in Dialog.Behavioral sciences (Basel, Switzerland) · 2018Article
- Clinical trial endpoints for patients with gliomas.Neuro-oncology practice · 2017Review
- Pediatric low-grade gliomas: implications of the biologic era.Neuro-oncology · 2017Review
- Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.Neuro-oncology · 2017Review
- Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report.Neuro-oncology · 2016Review
- Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.Neuro-oncology · 2016Review
- Neurological Health: Not Merely the Absence of Disease: Current Wellbeing Instruments Across the Spectrum of Neurology.American journal of lifestyle medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementSymptom occurrence impacts primary brain tumor patients from the time of diagnosis and often heralds recurrence. In addition, the therapy can also result in symptoms that may compound tumor-associated symptoms, further impacting the patient's function and overall quality of life. There is increasing recognition that clinical studies evaluating tumor response using only measures of tumor size on imaging or survival are inadequate in brain tumor patients. Many symptoms can only be assessed from the patient, and patient reported outcome measures have been developed and have adequate reliability and validity. These measures are beginning to be incorporated into clinical trials. Guidelines on their use and meaning are needed to standardize assessment across trials and facilitate measurement of clinical benefit.
Indexed as
Identifiers
25173554What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.